Ciraparantag (aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors ( rivaroxaban, apixaban and edoxaban), dabigatran, and heparins (including fondaparinux, low molecular weight heparins (LMWH), and unfractionated heparin).

Medical uses

Ciraparantag significantly reverses anticoagulation induced by a therapeutic dose of edoxaban within 10 minutes following injection. This return to normal haemostasis persists over 24 hours following a single intravenous dose of the drug. In addition to edoxaban, it also reverses the actions of LMWH and dabigatran.

Pharmacology

Mechanism of action

According to '' in vitro'' studies, the substance binds directly to anticoagulants via hydrogen bonds and charge-charge interactions from or to various parts of the molecule:

Chemistry

Ciraparantag consists of two L- arginine units connected with a piperazine containing linker chain.

References

Amino acid derivatives Antidotes Guanidines {{blood-drug-stub

Medical uses

Pharmacology

Mechanism of action

Chemistry

See also

References